Document:

Exhibit
10.17

 

UPDATE
AGREEMENT

 

This
Update Agreement (this “Agreement”) is entered effective as of the 1st day of February, 2021 (the “Effective
Date”), by and between ENDEXX Corporation, a Nevada corporation with offices located at 38246 North Hazelwood Circle, Cave
Creek, Arizona 85331 (“ENDEXX”), and M2B Funding Corp., a Florida corporation with offices located at 20801 Biscayne
Blvd., Suite 307, Aventura, Florida 33180 (“M2B”; and, collectively with ENDEXX, the “Parties”). The Parties
are signatories to (i) a Securities Purchase Agreement (the “SPA”), (ii) three Senior Secured Convertible Promissory
Notes1 (collectively, the “Notes”), and (iii) a related Security Agreement (the “Security Agreement”).
The Parties wish (x) to reaffirm the enforceability of the SPA and the Security Agreement, (y) to amend certain aspects of each
of the Notes, and (z) for ENDEXX to grant to M2B an option for the purchase of shares of common stock of ENDEXX, all as set forth
with more particularity hereinbelow.

 

In
consideration of these presents and for such other good and valuable consideration, the adequacy and receipt of which are hereby
acknowledged, the Parties, intending to be legally bound hereby, agree as follows:

 

1.
Amendments to the Notes. The Notes were issued pursuant to the SPA, dated October 11, 2019, and ENDEXX’s obligations
under the Notes were secured by the Security Agreement, dated October 11, 2019. As of the Effective Date, the sum of the currently
outstanding principal amount of the Notes and the accrued and unpaid interest is $2,331,102.87 (the “Current Outstanding
Balance”).

 

a.
Each of the Notes provides for a standard interest rate of 24% per annum and a default rate of 29% per annum. From and after the
Effective Date, the standard interest rate is hereby amended to 12% per annum and the rate of Default Interest (as defined in
each of the Notes) is hereby amended to 18% per annum.

 

b.
Each of the Notes provides for a Maturity Date (as defined in each of the Notes) that is 12 months following their respective
Issuance Dates. As of the Effective Date, the Maturity Date for all of the Notes is extended through and including January 31,
2022 (the “Extended Maturity Date”); provided, however, that ENDEXX shall (i) sell and issue 12,000,000
restricted shares of its common stock to M2B, delivery thereof on or about the Effective Date, for an aggregate purchase price
of $1,200.00 and (ii) tender to M2B monthly payments of $20,000.00, commencing on May 1, 2021, through and including January 1,
2022, which payments shall be applied to the Accrued Sum (as that term is defined in Section 1(c), below), whereupon all principal
and accrued and unpaid interest on the Notes shall be due and payable as of the Extended Maturity Date. Notwithstanding the above,
in the event that, from and after August 1, 2021, M2B is able to convert ENDEXX’s obligations under the Notes into unrestricted
shares of ENDEXX’s common stock and then to deposit such shares in a brokerage firm of M2B’s choice, then ENDEXX’s
monthly payment obligations hereunder shall be abated for each month in which M2B is able so to convert. For clarity, any such
abatement shall not act as an abatement, forgiveness, or forbearance of any accrual of interest under any of the Notes or a forbearance
or modification of the Extended Maturity Date of any of the Notes.

  

 

	1	The
                                         aggregate initial principal amount of the Notes is $2,000,000.00. The Note with an Issue
                                         Date of October 11, 2019, has an initial principal amount of $750,000.00; the Note with
                                         an Issue Date of November 11, 2019, has an initial principal amount of $700,000.00; and
                                         the Note with an Issue Date of January 16, 2020, has an initial principal amount of $550,000.00.

 

    	1

    	 

    

 

c.
Through and including February 1, 2021, ENDEXX was otherwise obligated to M2B for the sum of $331,102.87 (the “Accrued Sum”)
in addition to the principal amounts due under the Notes. The Accrued Sum included any and all interest at standard or Default
Interest rates and any and all penalties that may have been imposed upon ENDEXX in favor of M2B, as accrued through and including
January 31, 2021. ENDEXX agrees that, as of the Effective Date, the aggregate balance it owes to M2B under the Notes is $2,331,102.87,
on which sum interest shall continue to accrue at the 12% per annum standard interest rate, subject to any defaults by ENDEXX
in the performance of its obligations under any or all of the Notes.

 

d.
Except in respect of any Default Interest or other penalties that may have been imposed upon ENDEXX prior to the Effective Date,
the economic results of which are included in the Current Outstanding Balance, M2B waives any defaults under the Notes from and
after the Issue Date through and including the Effective Date and hereby declares that the Notes are not in default as of the
Effective Date.

 

e.
Each of the Notes provides for certain Conversion Rights (as defined in each of the Notes). From and after the Effective Date,
the Conversion Price (as defined in each of the Notes) is hereby amended to a fixed Conversion Price of $0.054 per share.

 

f.
Section 1.6(d) of each of the Notes is hereby amended to delete the phrase “Intentionally Left Blank” and to replace
it with the following: “If and whenever on or after the Effective Date, ENDEXX issues or sells, or is deemed to have issued
or sold, any shares of Common Stock (excluding shares of Common Stock underlying the Notes or the Option granted by ENDEXX to
M2B as of the Effective Date) for a consideration per share (the “New Issuance Price”) less than the Conversion
Price in effect immediately prior to such issuance or sale, then, immediately after such issue or sale, the Conversion Price then
in effect shall be reduced to an amount equal to the New Issuance Price.”

 

Except
as so amended hereby, all other aspects of Section 1.6(d) remain unamended.

 

g.
Section 1.9 of each of the Notes is hereby amended to change the end date of the Prepayment Period (as defined in each of the
Notes) from “[t]he period beginning 241 Days after the Issue Date and ending 360 Days following the Date of the Note”
to “[t]he period beginning on the Effective Date and ending on the Maturity Date, as amended; provided, however,
that any payments made in accordance with the provisions of Section 1(b) shall not be subject to the Prepayment Percentage (as
defined in each of the Notes); provided, however, further, that Borrower’s prepayment rights hereunder
are subject to its receipt of prior written consent of the Holder therefor, which consent may be withheld, delayed, denied, or
conditioned in the sole and absolute discretion of the Holder for any reason or for no reason.

 

2.
Reaffirmation and Acknowledgement of All Unamended Provisions of the Notes. ENDEXX hereby reaffirms all of its Covenants
set forth in Article II of each of the Notes, reaffirms and acknowledges the existence of all of the Events of Default and the
remedies therefrom set forth in Article III of each of the Notes, and reaffirms and acknowledges all of its obligations under
the various Miscellaneous Provisions set forth in Article IV of each of the Notes. ENDEXX further acknowledges that it, rather
than its currently wholly-owned subsidiary, CBD Unlimited, Inc, a Nevada corporation, is the “Borrower” (as defined
in each of the Notes) in each of the Notes.

 

    	2

    	 

    

 

3.
No other Amendments to the Notes. Except as set forth in this Agreement, each of the Parties agrees that none of the provisions
of the Notes has been amended, modified, or otherwise changed.

 

4.
Reaffirmation and Acknowledgment of All Representations and Warranties in the SPA. ENDEXX hereby reaffirms all of its Representations
and Warranties set forth in Article III of the SPA, reaffirms and acknowledges all of its Other Agreements set forth in Article
IV of the SPA, and reaffirms and acknowledges all of its obligations under the various the Miscellaneous Provisions set forth
in Article V of the SPA. ENDEXX further acknowledges that it, rather than its currently wholly-owned subsidiary, CBD Unlimited,
Inc, a Nevada corporation, is the “Company” (as defined in the SPA) in the SPA.

 

5.
Reaffirmation of the Enforceability of the SPA and the Security Agreement. ENDEXX hereby reaffirms that the executory provisions
of the SPA and all of the provisions of the Security Agreement remain in full force and effect and acknowledges the enforceability
of all of the provisions thereof. ENDEXX further acknowledges that it, rather than its currently wholly-owned subsidiary, CBD
Unlimited, Inc, a Nevada corporation, is the “Company” (as defined in the Security Agreement) in the Security Agreement.
Further, Section 1(a) of the Security Agreement is hereby amended to read as follows: “[c]ollateral” means
the collateral in which the Secured Party is granted a security interest by this Agreement and which shall include the following
real property and personal property of the Company, whether presently owned or existing or hereafter acquired or coming
into existence, wherever situated, and all additions and accessions thereto and all substitutions and replacements thereof, and
all proceeds, products and accounts thereof, including, without limitation, all proceeds from the sale or transfer of the Collateral
and of insurance covering the same and of any tort claims in connection therewith, and all dividends, interest, cash, notes, securities,
equity interest or other property at any time and from time to time acquired, receivable or otherwise distributed in respect of,
or in exchange for, any or all of the Pledged Securities (as defined below):

 

A
new Subsection (ix) is hereby inserted into the Security Agreement:

 

“That
certain parcel of improved real property located in Maricopa County, State of Arizona, with a common address of 38246 North Hollywood
Circle, Cave Creek, Arizona 85331; Maricopa County Arizona Parcel No. 212-08-011-B; and a legal description of MOON-RIDGE MCR
64-14 LOT 6 & ALSO TH PT OF ABAND RD LY SLY OF & ADJ TO S BNDRY LN LOT 6P/D 15942-217 EX TH PT DAF BEG SE COR LOT 6 TH
S ALG NLY PROLONGATION W LN LOT 3 9.25F TH N 59D 55M W ALG CENT LN SD ABAND RD 28.66F TH N 76D 20M E 30.25F TO PT E LN LOT 6 TH
S 20D 33M W ALG E LN 13.10F TPOB; Together with all buildings, improvement, and fixtures thereon.”

 

Current
Subsection (x) is hereby amended to be renumbered as Subsection (xi) and to read as follows: “[t]he products and proceeds
of all of the foregoing Collateral set forth in clauses (i)-(x) above.”

 

6.
Reserved.

 

7.
Issuances of Equity and Debt Securities. From and after October 11, 2019, ENDEXX sold and issued those shares of its capital
stock and sold and issued those certain debt instruments (whether or not directly or indirectly convertible into capital stock
of ENDEXX) that are listed on Exhibit 7 attached hereto. Any sale and issuance by ENDEXX of (i) additional shares of its capital
stock or (ii) debt instruments (whether or not directly or indirectly convertible into capital stock of ENDEXX) without the express,
prior written consent of M2B shall constitute an event of default hereunder. Upon such event, because of the economic and other
losses that may be directly or indirectly suffered by M2B thereby, ENDEXX agrees that, as liquidated damages and not as a penalty,
within three (3) days of the occurrence of each such event of default, ENDEXX shall issue to M2B 1,000,000 restricted shares of
common stock of ENDEXX without payment therefor.

 

    	3

    	 

    

 

8.
Miscellaneous Provisions.

 

a.
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.

 

b.
Incorporation of Sections of the SPA. The provisions of Sections 5.4 (Notices), 5.7 (Successors and Assigns), 5.8 (Third
Party Beneficiaries), 5.9 (Governing Law), 5.12 (Severability), 5.15 (Remedies), 5.19 (Saturdays, Sundays, Holidays, etc.), 5.20
(Construction), and 5.21 (Waiver of Jury Trial). For purposes of this Section 7(b) of this Agreement the term “Company”
in the SPA shall refer to ENDEXX and the term “Purchaser” shall refer to M2B.

 

c.
Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof
and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the Parties acknowledge
have been merged herein.

 

d.
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented, or amended except in a written
instrument signed, in the case of an amendment, by ENDEXX and M2B. No waiver of any default with respect to any provision, condition,
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition, or requirement hereof, nor shall any delay or omission of any party to exercise
any right hereunder in any manner impair the exercise of any such right.

 

e.
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.

 

*******
SIGNATURE PAGE FOLLOWS *******

 

    	4

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the
Effective Date.

 

	ENDEXX CORPORATION.	 	M2B
    FUNDING CORP.
	 	 	 
	By:	 	 	By:	 
	 	Todd
    Davis, Chief Executive Officer	 	 	Daniel
    Kordash, President

 

    	5

    	 

    

 

ISSUANCES
OF CAPITAL STOCK:

 

	Name
    of Issuee	 	Number
    of Shares	 	Class/Series	 	Consideration	 	Issuance
    Date

 

 

ISSUANCES
OF CONVERTIBLE INSTRUMENTS:

 

Equity:

 

	Name
    of Issuee	 	Number
    of Shares	 	Class/Series	 	Consideration	 	Issuance
    Date

 

Debt:

 

	Name
    of Holder	 	Face
    Amount	 	Int.
    Rate	 	Issue
    Date	 	Consideration/OID	 	$
    Outstanding	 	Convert
    Rate	 	Maturity
    Date

 

 

EXHIBIT
7Exhibit
10.18

 

CONVERTIBLE
NOTE PURCHASE AGREEMENT

 

This
Convertible Note Purchase Agreement (this “Agreement”) is dated as of January 22, 2021, by and between Apollo
Management SPV LLC, a Florida limited liability company with offices located at 7050 Aloma Avenue, Winter Park, Florida 32792
(“SPV” or the “Purchaser”), and Endexx Corporation, a Nevada corporation with offices located
at 38246 North Hazelwood Circle, Cave Creek, Arizona 85331 (“Endexx” or the “Company”).

 

WHEREAS,
Endexx is desirous of borrowing up to the aggregate sum of Two Million Dollars ($2,000,000.00) from SPV (the “Investment
Amount”), and SPV is desirous of initially lending a minimum of One Million Two Hundred Fifty Thousand Dollars ($1,250,000.00
(the “Initial Investment Amount”);

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act”), and/or Rule 506 promulgated thereunder, Endexx desires to issue and sell
to Purchaser, and Purchaser desires to purchase from Company, securities of the Company as more fully described in this Agreement;

 

WHEREAS,
the Purchaser desires that the Company grant it a Warrant (the “Warrant”) for the purchase of a calculable
number of shares of common stock at a calculable price per share on terms and conditions that the Purchaser and the Company are
willing to accept;

 

WHEREAS,
the Purchaser and the Company expect that the Company will become subject to Section 13 or 15(d) of the Exchange Act within 75
days of the date hereof and, prior to such occurrence, the following terms, among others, contained herein or in the Note, the
Warrant, or the Security Agreements may not be relevant or applicable to the transactions contemplated by these agreements: Average
Daily Dollar Volume; Buy-In; Default Conversion Price; DTC; DTC/FAST Program; DWAC eligible; Equity Line of Credit; Exchange Act
and related periodic reports; Marketplace Rules of the NASDAQ Stock Market; OTC; OTC Markets Group Inc.; Rule 144; Trading Day;
Variable Priced Equity Linked Instrument; and VWAP.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE
I.

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Notes (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:

 

“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.6.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board
of Directors” means the board of directors of Endexx.

 

    	1

    	 

    

 

“Business
Day” means any day except any Saturday, any Sunday, any day that is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Closing
Date(s)” means the Business Day(s) on which all of the Transaction Documents have been executed and delivered by the
applicable parties thereto in connection with a Closing, and all conditions precedent to (i) the Purchaser’s obligations
to pay the Subscription Amount as to such Closing and (ii) the Company’s obligations to deliver the Securities as to such
Closing, in each case, have been satisfied or waived.

 

“Closing(s)”
means the one or more closings of the purchase and sale of the Securities pursuant to Section 2.1.

 

“Closing
Statement” means the Closing Statement provided by Endexx to the Purchaser.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Company
Counsel” means Clark Hill PLC.

 

“Disclosure
Schedules” shall have the meaning ascribed to such term in Section 3.1.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $[_______] (other than trade accounts payable or for
services provided incurred in the ordinary course of business) and (y) the present value of any lease payments in excess of $[_______]
due under leases required to be capitalized in accordance with GAAP.

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).

 

“Intellectual
Property Security Agreement” means that certain intellectual property security agreement of the Company in favor of
the Purchaser, the form of which agreement is attached hereto as Exhibit D.

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other restriction.

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(m).

 

“Maximum
Rate” shall have the meaning ascribed to such term in Section 5.17.

 

“Note(s)”
means the 12% Senior Secured Convertible Promissory Note(s) due, subject to the terms therein, twelve (12) months from date of
issuance, issued by Endexx to Purchaser hereunder, in the form of Exhibit A attached hereto.

 

    	2

    	 

    

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Principal
Amount” means, as to the Purchaser, the amounts set forth below such Purchaser’s signature block on the signature
pages hereto next to the heading “Principal Amount,” in United States Dollars, which shall equal such Purchaser’s
Subscription Amount as to the applicable Closing.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.9.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities”
means the Notes and the Warrants.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Security
Agreement” means that certain security agreement of the Company in favor of the Purchaser, the form of which agreement
is attached hereto as Exhibit C.

 

“Security
Agreements” means the Security Agreement and Intellectual Property Security Agreement.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.

 

“Transaction
Documents” means all of the following agreements: this Agreement, the 12% Senior Secured Convertible Promissory Note,
the Warrant, the Registration Rights Agreement, the Security Agreement, the IP Security Agreement, the Preferred Stock Pledge
Agreement, and the Royalty Agreement.

 

“Warrant”
means that certain Common Stock Purchase Warrant of the Company granted to the Holder, the form of which Warrant is attached hereto
as Exhibit B.

 

ARTICLE
II.

PURCHASE AND SALE

 

2.1
Purchase. The Purchaser will purchase the Initial Investment Amount of Senior Secured Convertible Notes (“Note(s)”)
at the initial Closing (hereinafter, the “Initial Closing”). The Purchaser may purchase additional Notes at
subsequent Closings up to the aggregate Investment Amount.

 

    	3

    	 

    

 

2.2
Closing. On or about January 22, 2021 (the “Initial Closing Date”), upon terms and subject to conditions
set forth herein, the Company agrees to sell, and the Purchaser, agrees to purchase the Initial Investment Amount of Note(s) at
the Initial Closing and may purchase additional Notes at subsequent Closings up to the aggregate Investment Amount at subsequent
Closings, unless otherwise agreed. At the Initial Closing, the Company shall sell a Note for a purchase price of One Million Three
Hundred Fifty Thousand Dollars ($1,250,000.00) and SPV shall purchase such a Note, to be paid at the Initial Closing, in the initial
principal amount One Million Three Hundred Fifty Thousand Dollars ($1,250,000.00).

 

2.3
Deliveries. On the Initial Closing Date (except as noted or amended by mutual agreement),

 

(a)
Endexx shall deliver or cause to be delivered to the Purchaser the following:

 

(i)
this Agreement duly executed by Endexx;

 

(ii)
the Note duly executed by Endexx;

 

(iii)
the Warrant duly executed by Endexx;

 

(iv)
the Security Agreements duly executed by Endexx; and

 

(vii)
such other documents, certificates, instruments, and other writings as Purchaser’s counsel may reasonably request.

 

(b)
Purchaser shall deliver or cause to be delivered to Endexx the following:

 

(i)
this Agreement duly executed by Purchaser;

 

(ii)
the Security Agreements duly counter-executed by Purchaser; and

 

(iv)
such other documents, certificates, instruments, and other writings as Endexx’s counsel may reasonably request.

 

2.4
Closing Conditions.

 

(a)
The obligations of Endexx hereunder in connection with each of the Closings are subject to the following conditions being satisfied:

 

(i)
the accuracy in all material respects on the applicable Closing Date of the representations and warranties of the Purchaser contained
herein (unless, as of a specific date therein, in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the applicable Closing Date
shall have been performed;

 

(iii)
the delivery by the Purchaser of the items set forth in Section 2.3(b) of this Agreement; and

 

(iv)
there shall have been no Material Adverse Effects with respect to the Company since the date hereof.

 

    	4

    	 

    

 

(b)
The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being satisfied:

 

(i)
the accuracy in all material respects on the applicable Closing Date of the representations and warranties of Endexx contained
herein (unless, as of a specific date therein, in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants, and agreements of Endexx required to be performed at or prior to the applicable Closing Date shall
have been performed;

 

(iii)
the delivery by Endexx of the items set forth in Section 2.3(a) of this Agreement; and

 

(iv)
there shall have been no Material Adverse Effects with respect to the Company since the date hereof.

 

ARTICLE
III.

REPRESENTATIONS AND WARRANTIES

 

3.1
Representations and Warranties of the Company. Except as set forth in the “Disclosure Schedules,” which Disclosure
Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and
warranties to the Purchaser as of the date hereof.

 

(a)
Subsidiaries. The Company’s subsidiaries are as set forth on Schedule 3.1(a).

 

(b)
Organization and Qualification. Endexx is an entity duly incorporated, validly existing, and in good standing under the
laws of Nevada, with the requisite power and authority to own and use its properties and assets and to carry on its business as
currently conducted. The Company is not in violation or default of any of the provisions of its respective certificate or articles
of incorporation, bylaws or other organizational or charter documents. The Company is duly qualified to conduct business and is
in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the
case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document; (ii) a material adverse effect on the results of operations, assets, business, prospects
or condition (financial or otherwise) of the Company; or (iii) a material adverse effect on the Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii), or (iii), a “Material
Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.

 

    	5

    	 

    

 

(c)
Authorization; Enforcement. Endexx has the requisite power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the
part of such Company and no further action is required by such Company, its Board of Directors, stockholders, or members, as applicable,
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by such Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of such Company enforceable against
that Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

(d)
No Conflicts. The execution, delivery and performance of Endexx of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of
incorporation, bylaws or other organizational or charter documents; (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien (except Liens in favor
of the Purchaser) upon any of the properties or assets of the Company, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company debt or otherwise) or other understanding to which such Company is a party or by which any property
or asset of the Company is bound or affected; or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.

 

(e)
Filings, Consents, and Approvals. Endexx is not required to obtain any consent, waiver, authorization, or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local, or other governmental authority
or other Person in connection with the execution, delivery, and performance by the Company of the Transaction Documents.

 

(f)
Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid, and non-assessable, free, and clear of all Liens imposed by
the Company other than restrictions on transfer provided for in the Transaction Documents.

 

    	6

    	 

    

 

(g)
Capitalization. The capitalization of Endexx is as set forth on Schedule 3.1(g), which Schedule 3.1(g) also
includes the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
Endexx has not issued any capital stock other than as listed on Schedule 3.1(g), other than pursuant to the exercise of
employee stock options, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase
plans, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of Closing. Other
than with regard to Exempt Issuances (as that term is defined in Section 5(c) of the Note), no Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale of the Securities and securities issued to employees, officers, or directors
or former employees, officers, or directors and other service providers or former service providers of the Company, there are
no outstanding options, warrants, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or
acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become
bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not
obligate any Company to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not
result in a right of any holder of that Company’s securities to adjust the exercise, conversion, exchange or reset price
under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and non-assessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further
approval or authorization of any stockholder or other equity holder, as applicable, the Board of Directors or others is required
for the issuance and sale of the Securities. Other than as set forth on Schedule 3.1(g), there are no stockholders’
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 

(h)
[Reserved.]

 

(i)
Material Changes. (i) there has been no event, occurrence, or development that has had or that could reasonably be expected
to result in a Material Adverse Effect; (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company’s financial statements pursuant to GAAP; (iii) the Company has not altered its
method of accounting; (iv) the Company has not declared or made any dividend or distribution of cash or other property to its
stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock; and (v) the
Company has not issued any equity securities to any officer, director or Affiliate except for the issuance of the Securities contemplated
by this Agreement, or the Exempt Issuances. No event, liability, fact, circumstance, occurrence, or development has occurred or
exists or is reasonably expected to occur or exist with respect to the Company or its business, properties, operations, assets,
or financial condition that would be required to be disclosed by the Company.

 

(j)
Litigation. There is no action, suit, inquiry, notice of violation, proceeding, or investigation pending or, to the knowledge
of the Company, threatened against or affecting the Company, or any of its respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”),
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect, and neither the Company, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.

 

    	7

    	 

    

 

(k)
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s employees
is a member of a union that relates to such employee’s relationship with the Company, and the Company is not a party to
a collective bargaining agreement, and the Company believes that its relationships with its employees are good. To the knowledge
of the Company, no executive officer of the Company is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract
or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer
does not subject the Company to any liability with respect to any of the foregoing matters. The Company is in compliance with
all U.S. federal, state, local, and foreign laws, and regulations relating to employment and employment practices, terms and conditions
of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.

 

(l)
Compliance. Except as set forth in Schedule 3.1(l), the Company: (i) is not in default under or in violation of
(and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the
Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any
indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived), (ii) is not in violation of any judgment, decree or order
of any court, arbitrator or other governmental authority or (iii) is not and has not been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters,
except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(m)
Regulatory Permits. The Company possesses all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses, as applicable or on Schedule
3.1(m), except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse
Effect (“Material Permits”), and neither the Company has received any notice of proceedings relating to the revocation
or modification of any Material Permit.

 

(n)
Title to Assets. The Company has good and marketable title in fee simple to all real property owned by it and good and
marketable title in all personal property owned by it that is material to the business of the Company, in each case free and clear
of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with
the use made and proposed to be made of such property by the Company and (ii) Liens for the payment of federal, state or other
taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company are held by it under valid, subsisting,
and enforceable leases with which the Company is in compliance.

 

    	8

    	 

    

 

(o)
Intellectual Property. The Company has rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar
rights as described on Schedule 3.1(o) as necessary or required for use in connection with their business as presently
conducted and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property
Rights”). The Company has not received a notice (written or otherwise) that any of the Intellectual Property Rights has
expired, terminated, or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. The Company has not received a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have
a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is
no existing infringement by another Person of any of the Intellectual Property Rights. The Company has taken reasonable security
measures to protect the secrecy, confidentiality, and value of all of its intellectual properties, except where failure to do
so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(p)
Transactions with Affiliates and Employees. Except as set forth in Schedule 3.1(p) and for the Exempt Issuances,
none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is
presently a party to any transaction with the Company (other than for services as employees, officers, and directors), including
any contract, agreement or other arrangement, providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, providing for the borrowing of money from or lending of money to, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for: (i) payment of salary or consulting fees for services rendered; (ii) reimbursement for expenses
incurred on behalf of the Company; and (iii) other employee benefits, including stock option or stock award agreements.

 

(q)
[Reserved.]

 

(r)
Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank, or other Person with respect to the transactions contemplated
by the Transaction Documents. The Purchaser shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.

 

(s)
Private Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchaser
as contemplated hereby.

 

(t)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become an “investment company”
subject to registration under the Investment Company Act of 1940, as amended.

 

(u)
Registration Rights. Other than with regard to the Exempt Issuances, no Person has any right to cause any Company to affect
the registration under the Securities Act of any securities of the Company.

 

    	9

    	 

    

 

(v)
[Reserved.]

 

(w)
[Reserved.]

 

(x)
Disclosure. The Company understands and confirms that the Purchaser will rely on the representations herein in effecting
transactions in securities of the Company. All of the disclosures furnished by or on behalf of the Company to the Purchaser regarding
the Company, and their business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement,
are true and correct and do not contain any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company
acknowledges and agrees that the Purchaser has not made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 hereof.

 

(y)
No Integrated Offering. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would
require the registration of any such securities under the Securities Act.

 

(z)
No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of
the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only
to the Purchaser within the meaning of Rule 501 under the Securities Act.

 

(aa)
Foreign Corrupt Practices. The Company has not to its knowledge, nor any agent or other person acting on behalf of the
Company: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses
related to foreign or domestic political activity; (ii) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds; (iii) failed to disclose fully
any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation
of law; or (iv) violated in any material respect any provision of FCPA.

 

(bb)
Accountants. The Company’s accounting firm is set forth on Schedule 3.1(bb) of the Disclosure Schedules. To
the knowledge and belief of the Company, such accounting firm is registered with the Public Company Accounting Oversight Board.

 

(cc)
No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably
anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the
Company.

 

(dd)
Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and
any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated thereby is merely incidental to the Purchaser’s purchase of the Securities. The Company
further represents to the Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

    	10

    	 

    

 

(ee)
[Reserved.]

 

(gg)
Office of Foreign Assets Control. Neither the Company, and to the Company’s knowledge, no director, officer, agent,
employee, or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (“OFAC”).

 

(hh)
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the
Purchaser’s request.

 

(ii)
Bank Holding Company Act. Neither the Company nor any of Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal
Reserve”). Neither the Company nor any of its Affiliates owns or controls, directly or indirectly, five percent (5%)
or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of
a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA
and to regulation by the Federal Reserve.

 

(jj)
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company (i) has made or filed all United States federal, state and local income and all foreign
income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any
such claim.

 

(kk)
Seniority. No Indebtedness or other claim against the Company is senior to the Notes in right of payment, whether with
respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security
interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as
to the property covered thereby).

 

(ll)
[Reserved.]

 

    	11

    	 

    

 

(mm)
Money Laundering. The operations of the Company are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering
Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company
or any Subsidiary, threatened.

 

(nn)
Related Party Transactions. All related party transactions have been consummated in accordance with all applicable laws
and governing agreements, including, without limitation, those laws applicable to the diversion of a corporate opportunity of
each Company or any of Affiliate of such Company or any Affiliate of any principal of that Company. In each instance, the particular
related party transaction has been approved by a majority of the disinterested directors of the Company, after full disclosure
has been made to each board member of the pertinent facts of the proposed transaction. Each such related party transaction has
been consummated on terms and conditions that are equal or more favorable to the Company than a transaction with an unaffiliated
third party knowing all the facts and under no compulsion to consummate such transaction.

 

Purchaser
acknowledges and agrees that the representations contained in Section 3.1 shall not modify, amend, or affect the Company’s
rights to indemnification or to rely on such Purchaser’s representations and warranties contained in this Agreement or any
representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or
delivered in connection with this Agreement or the consummation of the transactions contemplated hereby.

 

3.2
Representations and Warranties of the Purchaser. Purchaser hereby represents and warrants as of the date hereof and as
of the applicable Closing Date to the Company as follows (unless as of a specific date therein):

 

(a)
Organization; Authority. Purchaser is an entity duly formed, validly existing, and in good standing under the laws of the
State of Florida with full limited liability company power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of
the Transaction Documents and performance by the Purchaser of the transactions contemplated by the Transaction Documents have
been duly authorized by all necessary corporate, partnership, limited liability company, or similar action, as applicable, on
the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser, and when
delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the
Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally; (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies; and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

    	12

    	 

    

 

(b)
Own Account. Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling the Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of the Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons
to distribute or regarding the distribution of the Securities in violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such Purchaser’s right to sell the Securities in compliance with applicable
federal and state securities laws). Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

 

(c)
Purchaser Status. At the time Purchaser was offered the Securities, it was, and as of the date hereof it is, an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) under the Securities Act.

 

(d)
Experience of Such Purchaser. Purchaser, either alone or together with its representatives, has such knowledge, sophistication,
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e)
General Solicitation. Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine, or similar media or broadcast over television or
radio or presented at any seminar or any other general solicitation or general advertisement.

 

(f)
Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, Purchaser has
not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with Purchaser, executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the
material terms of the transactions contemplated hereunder and ending immediately Upon the repayment in full (whether by cash or
conversion) of all of the Notes sold by the Company in connection with this Agreement. Notwithstanding the foregoing, in the case
of Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of Purchaser’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
Other than to other Persons party to this Agreement, Purchaser has maintained the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar
transactions in the future.

 

The
Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend, or affect Purchaser’s
rights to indemnification or to rely on the Company’s representations and warranties contained in this Agreement or any
representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or
delivered in connection with this Agreement or the consummation of the transactions contemplated hereby.

 

    	13

    	 

    

 

ARTICLE
IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1
Transfer Restrictions.

 

(a)
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of
Securities other than pursuant to an effective registration statement or Rule 144, to the Company of Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall
be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Securities under the Securities Act. The Company shall bear the costs of each such opinion. As a condition of transfer, any such
transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser
under this Agreement.

 

(b)
The Purchaser agrees to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the
following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED
IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement
and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees
or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel
of the pledgee, secured party, or pledgor shall be required in connection therewith. Further, no notice shall be required of such
pledge. At the Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of Securities may reasonably request in connection with a pledge or transfer of the Securities.

 

    	14

    	 

    

 

4.2
[Reserved.]

 

4.3
[Reserved.]

 

4.4
Integration. The Company shall not sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of
any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities
in a manner that would require the registration under the Securities Act of the sale of the Securities.

 

4.5
[Reserved.]

 

4.6
Stockholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, or the Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue
of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchaser.

 

4.7
[Reserved.]

 

4.8
Use of Proceeds. The Company shall use the net proceeds hereunder solely in the manner specified in Section 7(k) of the
Notes.

 

    	15

    	 

    

 

4.9
Indemnification of Purchaser. Subject to the provisions of this Section 4.9, the Company, will indemnify and hold Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls
the Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser
Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation
that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations,
warranties, covenants, or agreements made by each Company in this Agreement or in the other Transaction Documents or (b) any action
instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of
the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is based upon a breach of such Purchaser Party’s representations, warranties, or covenants
under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or
any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes
fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect
of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing,
and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to such
Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after
a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion
of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Companies shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.
The Company will be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without
the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only
to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations,
warranties, covenants, or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The
indemnification required by this Section 4.9 shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in
addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the
Company may be subject to pursuant to law.

 

ARTICLE
V.

MISCELLANEOUS

 

5.1
Fees and Expenses. The Company shall deliver to the Purchaser, prior to the applicable Closing, a completed and executed
copy of the Closing Statement, attached hereto as Annex A. Except as expressly set forth in the Transaction Documents to the contrary,
each party shall pay the fees and expenses of its advisers, counsel, accountants, and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution, delivery, and performance of this Agreement; provided
that, at the Initial Closing, the Company shall pay the to the manager of the Purchaser a non-accountable fee of $40,000 and the
Company shall pay its legal fees out of its proceeds at the Initial Closing. The Company shall pay all stamp taxes and other taxes
and duties levied in connection with the delivery of any Securities to the Purchaser.

 

5.2
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits, and schedules.

 

5.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 12:00 noon
(New York City time) on a Business Day; (ii) the next Business Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Business
Day or later than 12:00 noon (New York City time) on any Business Day; (iii) the second (2nd) Business Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service; or (iv) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature
pages attached hereto.

 

    	16

    	 

    

 

5.4
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented, or amended except in a written
instrument signed by the Company and a majority-in-interest of the Principal Amount of Notes outstanding as of the date of such
waiver, modification, supplement, or amendment. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of
any other provision, condition, or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.

 

5.5
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.

 

5.6
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Purchaser (other than by merger). The Purchaser may assign any or all of its rights under this Agreement to any
Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound,
with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to “Purchaser.”

 

5.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

5.8
Governing Law. All questions concerning the construction, validity, enforcement, and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without
regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations,
enforcement, and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees, or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of Miami. Each party hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the City of Miami, Miami-Dade County, for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit, or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action, suit or
proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred
with the investigation, preparation, and prosecution of such action or proceeding.

 

    	17

    	 

    

 

5.9
Survival. The representations and warranties contained herein shall survive each of the Closings and the delivery of the
Securities.

 

5.10
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page was an original thereof.

 

5.11
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants, and restrictions without including any
of such that may be hereafter declared invalid, illegal, void, or unenforceable.

 

5.12
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand, or option under
a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then
Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice,
demand or election in whole or in part without prejudice to its future actions and rights.

 

5.13
Replacement of Securities. If any certificate or instrument evidencing any of the Securities is mutilated, lost, stolen,
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in
the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft, or destruction. The applicant for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance
of such replacement Securities.

 

5.14
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, Purchaser and Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.

 

5.15
Payment Set Aside. To the extent that Company makes a payment or payments to Purchaser pursuant to any Transaction Document
or Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then, to the extent of any such restoration, the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

    	18

    	 

    

 

5.16
Usury. To the extent it may lawfully do so, Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now
or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by Purchaser in order
to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any
Transaction Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents
for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of
them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction
Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to
the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof,
the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from
the effective date thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever,
interest in excess of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction
Documents, such excess shall be applied by the Purchaser to the unpaid principal balance of any such indebtedness or be refunded
to the Company, the manner of handling such excess to be at the Purchaser’s election.

 

5.17
[Reserved.]

 

5.18
Liquidated Damages. Company’s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages
and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated
damages or other amounts are due and payable shall have been canceled.

 

5.19
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

5.20
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto.

 

5.21
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

(Signature
Pages Follow)

 

    	19

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Convertible Note Purchase Agreement to be duly executed by its authorized signatories
as of the date first indicated above.

 

	ENDEXX
    CORPORATION	 
	 	 
	By:	                  	 
	Name:	 	 
	Title:	 	 

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	20

    	 

    

 

[PURCHASER SIGNATURE PAGES TO

CONVERTIBLE
NOTE PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Convertible Note Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.

 

Name
of Purchaser: _________________________________________________________________

 

Signature
of Authorized Signatory of Purchaser: _______________________________________________________

 

Name
of Authorized Signatory: ____________________________________________________________________

 

Title
of Authorized Signatory: ________________________________________________

 

E-mail
Address of Authorized Signatory: ________________________________________

 

Facsimile
Number of Authorized Signatory: ______________________________________

 

Address
for Notice to Purchaser: ______________________________________________

 

_______________________________________________________________________

  

Address
for Delivery of Securities to Purchaser (if not same as address for notice):

 

_______________________________________________________________________

 

_______________________________________________________________________

 

 

Closing
Principal Amount: $ __________________________________________________

 

Closing
Subscription Amount (Inclusive of the $ ______________________ Note Subscription Amount):

 

$ _________________________________________

 

EIN
Number: __________________________________________

 

    	21

    	 

    

 

Annex
A

 

CLOSING
STATEMENT

 

Pursuant
to the attached Purchase Agreement, dated as of the date hereto, the Purchaser shall purchase Note(s) from Endexx Corporation,
a Nevada corporation (the “Company”). All funds will be wired into an account maintained by the Company. All
funds will be disbursed in accordance with this Closing Statement.

 

Disbursement
Date: January 22, 2021

 

	I.
PURCHASE PRICE 
	 	 	 
	 	 	 	 
	Gross Proceeds to be Received	 	$	1,250,000.00	 
	 	 	 	 	 
	II.
DISBURSEMENTS 
	 	 	 	 
	 	 	 	 	 
	M2B Funding Corp.	 	$	992,226.00	 
	Odin Associates, LLC	 	$	65,790.00	 
	Clark Hill PLC	 	$	15,000.00	 
	Endexx Corporation	 	$	176,984.00	 
	 	 	$		 
	 	 	 	 	 
	Total Amount Disbursed:	 	$	1,250,000.00	 

 

WIRE
INSTRUCTIONS:

 

As
provided.

 

Duly
executed this 22 day of January, 2021:

 

	__________________on
    behalf of	 
	By:	                                          	 
	Name:	 	 
	Title:	 	 

 

    	22

    	 

    

 

SECTION
3.1(A)

 

CBD
Unlimited, a wholly-owned subsidiary

Global
Solaris Group, LLC, a wholly-owned subsidiary

Greenleaf
Consulting LLC, a wholly-owned subsidiary

Cann
Can LLC, a wholly owned-subsidiary

Together
One Step Closer, LLC, a wholly-owned subsidiary

PhytoLabs
LLC, a wholly-owned subsidiary

Go
Green Global Enterprises, Inc., a wholly-owned subsidiary

CBD
Health Solutions, a wholly-owned subsidiary

Kush,
Inc., a wholly-owned subsidiary

CBD
Life Brands, Inc., a wholly-owned subsidiary

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]